Results 91 to 100 of about 4,402,031 (267)

Politics vs Market [PDF]

, 2006
As China's demand for energy grows, so does its dependence on imported oil. Currently, over 40 percent of China's total oil consumption derives from foreign sources making a supply disruption of the oil import routes an unthinkable blow to its national ...
Mao Yushi
core  

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Critical questions in diabetes management: What are the most compelling challenges and how can we handle them? [PDF]

Int J Cardiol Cardiovasc Risk Prev, 2022
Sonmez A, Haymana C, Demirci I, Cesur M, Rizzo M, Tasci I.   +5 more
europepmc   +1 more source

Edge-Stable Equimatchable Graphs

, 2018
A graph $G$ is \emph{equimatchable} if every maximal matching of $G$ has the same cardinality. We are interested in equimatchable graphs such that the removal of any edge from the graph preserves the equimatchability.
Deniz, Zakir, Ekim, Tınaz
core   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Point: Benchmarking can supplement transportability to answer critical questions about the effectiveness of antenatal corticosteroid administration. [PDF]

Paediatr Perinat Epidemiol, 2023
Caniglia EC, Hinkle SN.
europepmc   +1 more source

Disavowal. Distinction and Repetition: Alain Badiou and the Radical Tradition of Antisemitism [PDF]

, 2019
My focus in this chapter on the militant French philosopher, Alain Badiou, emerges from my work into the various ways that the Shoah has been incorporated into antisemitic ways of thinking.
Seymour, D.
core  

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Racial Microaggressions: Critical Questions, State of the Science, and New Directions. [PDF]

Perspect Psychol Sci, 2021
Williams MT.
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source